AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

Core Insights - Amgen has launched a new direct-to-patient program called AmgenNow, offering Repatha at a monthly price of $239, which is nearly 60% lower than the current U.S. list price [2][3] - The program aims to support patients, including those uninsured or with high-deductible health plans, making it easier for them to access Repatha, which has shown significant clinical benefits in reducing major adverse cardiovascular events [1][2] - Repatha is a PCSK9 inhibitor that has been studied for 15 years in over 50 clinical trials involving more than 57,000 patients, demonstrating its effectiveness in lowering LDL cholesterol levels [3][4] Pricing and Accessibility - The AmgenNow program is available to all Repatha patients, including those on government programs like Medicare and Medicaid, and does not require prior authorization or step therapy from insurers [2][3] - The new pricing structure positions Repatha as the lowest-priced option among economically developed G-7 countries, reflecting Amgen's commitment to making medications more accessible [2][3] Clinical Background - Repatha works by inhibiting PCSK9, which allows for increased recycling of LDL receptors, thereby lowering LDL cholesterol levels in the blood [3] - The drug is approved in over 74 countries, including the U.S., Japan, Canada, and all EU member states, with applications pending in other regions [4] Indications and Safety Information - Repatha is indicated for adults and pediatric patients aged 10 years and older with specific types of hypercholesterolemia, and it is used as an adjunct to diet and exercise [7] - Important safety information includes contraindications for patients with a history of serious hypersensitivity reactions to evolocumab, and common adverse reactions reported include nasopharyngitis and upper respiratory tract infections [6][8]